Concentrate Products Sales was Rockwell Medical’s largest revenue line in fiscal 2025, bringing in $60.36M of $60.68M (99%).
| Timing of Transfer of Good or Service | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Concentrate Product Sales | $62.72M | — | — | — | |||||
| Concentrate Products Sales | — | — | $92.26M | $60.36M | |||||
| Concentrate Products | — | $72.87M | — | — | |||||
| Total Concentrate Products | $6.45M | — | — | — | |||||
| License | — | — | — | — | |||||
| Concentrate Product License Fee | — | — | — | — | |||||
| Drug Revenues | — | $2.34M | — | — | |||||
| Total Drug Products | $1.16M | — | — | — | |||||
| Drug Revenue | — | — | — | — | |||||
| Drug Product Sales | $903.00K | — | — | — | |||||
| Drug License Fee | $256.00K | — | — | — | |||||
| License Fees | — | — | $46.00K | $325.00K | |||||
| Total | $71.48M | $75.21M | $92.30M | $60.68M |
Rockwell Medical brought in $60.68M from its two revenue lines in fiscal 2025, the year ended December 31, 2025. That is less than the $68.93M it reports by geography, so these revenue lines do not cover all of its revenue. Concentrate Products Sales was the largest at $60.36M (99.5%), ahead of License Fees at $325.00K (0.5%).
Rockwell Medical began breaking out Concentrate Products Sales in fiscal 2024 and License Fees in fiscal 2024. Rockwell Medical stopped reporting Concentrate Products ($72.87M in fiscal 2023), Concentrate Product Sales ($62.72M in fiscal 2022), Total Concentrate Products ($6.45M in fiscal 2022) and four others as separate revenue lines.
Concentrate Product Sales - Point-In-Time was Rockwell Medical’s largest revenue line in fiscal 2025, bringing in $60.36M of $60.68M (99%).
| Timing Of Transfer Of Good Or Service | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|
| Concentrate Product Sales - Point-In-Time | — | — | $92.26M | $60.36M | ||||
| Product Sales – Point-In-Time | — | $72.87M | — | — | ||||
| Product Sales - Point-In-Time | $62.72M | — | — | — | ||||
| Point-In-Time | — | — | — | — | ||||
| License Fee – Over Time | $256.00K | $2.34M | $46.00K | $325.00K | ||||
| Over-Time | — | — | — | — | ||||
| Total | $62.97M | $75.21M | $92.30M | $60.68M |
Rockwell Medical brought in $60.68M from its two revenue lines in fiscal 2025, the year ended December 31, 2025. That is less than the $68.93M it reports by geography, so these revenue lines do not cover all of its revenue. Concentrate Product Sales - Point-In-Time was the largest at $60.36M (99.5%), ahead of License Fee – Over Time at $325.00K (0.5%).
Rockwell Medical began breaking out Concentrate Product Sales - Point-In-Time in fiscal 2024, when it brought in $92.26M. Rockwell Medical stopped reporting Product Sales – Point-In-Time ($72.87M in fiscal 2023) and Product Sales - Point-In-Time ($62.72M in fiscal 2022) as separate revenue lines.
U.S was Rockwell Medical’s largest region in fiscal 2025, bringing in $60.36M of $68.93M (88%).
| Geography | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|
| U.S | $62.72M | $72.87M | $92.26M | $60.36M | |||||
| United States | — | — | — | — | |||||
| Rest Of World | $6.45M | $6.93M | $9.19M | $8.58M | |||||
| Non-Us | — | — | — | — | |||||
| Total | $69.16M | $79.80M | $101.44M | $68.93M |
Rockwell Medical brought in $68.93M from its two regions in fiscal 2025, the year ended December 31, 2025. That was down 32.0% from $101.44M in fiscal 2024. U.S was the largest at $60.36M (87.6%), ahead of Rest Of World at $8.58M (12.4%).
Compared with fiscal 2024, Rest Of World fell 6.6% to $8.58M and U.S fell 34.6% to $60.36M. From fiscal 2022 to 2025, combined revenue from these regions fell from $69.16M to $68.93M, a compound annual decline of 0.1%. U.S's share of the total fell from 90.7% to 87.6%.
Rockwell Medical (RMTI) reports its revenue by timing of transfer of good or service and by geography. In fiscal 2025, Concentrate Products Sales was its largest revenue line, bringing in $60.36M (99.5% of the total), followed by License Fees at $325.00K (0.5%).
Concentrate Products Sales was Rockwell Medical's largest revenue line in fiscal 2025, bringing in $60.36M, or 99.5% of the $60.68M total across its two revenue lines.
U.S was Rockwell Medical's largest region in fiscal 2025, bringing in $60.36M, or 87.6% of the $68.93M total across its two regions.
Every figure comes from Rockwell Medical's annual financial filings, as reported. Each line keeps the name Rockwell Medical gives it, and years follow its fiscal calendar.
Rockwell Medical's revenue by timing of transfer of good or service goes back to fiscal 2017, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.